Pre-treatment expression data from neoadjuvant platinum & bevacizumab treated triple negative breast cancer patients

GSE103668

Homo sapiens

18 Downloadable Samples

Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description

Gene expression data from 21 triple negative breast cancer samples treated with cisplatin & bevacizumab in the neoadjuvant setting as part of a clinical trial.

PubMed ID

29452344

Publication Title

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Total Samples

Submitter’s Institution

Technical University of Denmark

Authors

Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL

Source Repository

Gene Expression Omnibus (GEO)

No rows found